Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: gsk + 22,000 + 0.31  Related to the article below (Last Update: 8/5/2008)

GSK's cost-cutting put to the test
The Press Association - Jul 19, 2008
... jobs may go under its "operational excellence" programme, although GSK has yet to outline how many of its 22000-strong UK workforce will be affected. ...
Shire Delivers Strong Quarter: Driven by $243m of New Product ...
MarketWatch - Jul 31, 2008
... more than 500 additional sales representatives from TAP which will increase the reach and frequency of sales calls covering an additional 22000 doctors. ...SHPGY
Singapore Science at 2008 Euroscience Open Forum
innovations report, Germany - Jul 18, 2008
It has currently more than 22000 researchers from more than 50 countries including Austria, Czech Republic, France, Germany, Greece, Hungary, Italy, Poland, ...
GSK and Rolls in spotlight as half-year results due
nebusiness.co.uk, UK - Jul 21, 2008
... jobs may go under its ?operational excellence? programme, although GSK has yet to outline how many of its 22000-strong UK workforce will be affected. ...
Source: Google News

Baculovirus-mediated expression and characterisation of rat glycogen synthase kinase-3?, the … -
K HUGHES, BJ PULVERER, P THEOCHAROUS, JR WOODGETT - European Journal of Biochemistry, 1992 - Blackwell Synergy
... (GSK-3) has demonstrated the existence of a novel form, termed GSK-3/l, which is
highly related to the well characterised GSK-3a protein but ... GSK-3 was ...

Rapid Hepatitis B Immunisation for the Traveller*: Comparison of Two Accelerated Schedules with a 2- … -
HL Bock - BioDrugs, 2003 - biodrugs.adisonline.com
... received intramuscular recombinant hepatitis B vaccine (Engerix-B ? 2, GlaxoSmithKline
Biologicals, Rixensart ... L for the day 0, 7, 21 schedule; and >22000 IU/L ...

[PDF] The Leading Global Society for Healthcare Technology -
I Board, B Roczniak - ispe.org
... Art Liem Director al15552@gsk.com Glaxo Smith Kline Inc. ... Encore Design &Tech. Inc
22000 Trans Canada Hwy., Baie D'Urfe, Quebec H9X 4B4 Bus: 514-457-8800 Ext. ...

TETRACYCLIC MONOAMINE REUPTAKE INHIBITORS FOR TREATMENT OF CNS DISEASES AND DISORDERS -
M Mesic, M Mercep, D Pesic, R Rupcic, B Stanic - EP Patent 1,846,414, 2007 - freepatentsonline.com
... 10000 Zagreb, HR) Pesic, Dijana (Prokljanska 18, 22000 Sibenik, HR ... Click for automatic
bibliography generation. Assignee: Glaxosmithkline, Istrazivacki Centar ...
-

USE OF 3-AZA-1-OXA-DIBENZO ie, h/i AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR … -
M Mercep, M Mesic, D Pesic, I Dzapo - EP Patent 1,684,766, 2007 - freepatentsonline.com
... 10 0000 Zagreb, HR) Pesic, Dijana (Prokljanska 18, 22000 Sibenik, HR ... Click for automatic
bibliography generation. Assignee: Glaxosmithkline, Istrazivacki Centar ...
-

USE OF 1, 3-DIAZA-DIBENZO [e, h] AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE … -
M Mercep, M Mesic, R Rupcic, D Pesic - EP Patent 1,684,749, 2007 - freepatentsonline.com
... 5, 10000 Zagreb, HR) Pesic, Dijana (Prokljanska 18, 22000 Sibenik, HR ... Click for
automatic bibliography generation. Assignee: Glaxosmithkline, Istrazivacki Centar ...
-

USE OF 2-THIA-DIBENZO [E, H] AZULENES FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM … -
M Mercep, M Mesic, D Pesic, I Ozimec Landek, B … - EP Patent 1,684,702, 2007 - freepatentsonline.com
... 8, 10000 Zagreb, HR) Pesic, Dijana (Prokljanska 18, 22000 Sibenik, HR ... Click for
automatic bibliography generation. Assignee: Glaxosmithkline, Istrazivacki Centar ...
-

USE OF 1-THIA-DIBENZO E, H AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE … -
M Mercep, M Mesic, M Modric, D Pesic, D Kidemet - EP Patent 1,684,751, 2007 - freepatentsonline.com
... 10000 Zagreb, HR) Pesic, Dijana (Prokljanska 18, 22000 Sibenik, HR ... Click for automatic
bibliography generation. Assignee: Glaxosmithkline, Istrazivacki Centar ...
-

Nuffield Council on Bioethics issues consultation paper on personalized medicines -
I President - Pharmacogenomics, 2003 - Future Medicine
... GlaxoSmithKline and Beyond Genomics enter evaluation agreement ... ?We are excited that
GSK, a world leader in pharmaceutical inovation, is evaluating our ...

?? ?? ? ??
?? ? - ?? ? ?, 2003 - ????
... 6???8??,?????22000?,??671 ... 2O ????M kt L 2002;29(
39),18 (????) 01084 GSK/ImmunoGen??????? ...

Source: Google Scholar
 

GlaxoSmithKline supports World Health Organization efforts to strengthen global pandemic preparedness plans

Issued – 2 May 2007 - GlaxoSmithKline [GSK: NYSE] today commended the commitment of the World Health Organization (WHO) to progress plans for ensuring that the world’s most vulnerable people are protected in the event of a pandemic. Key elements of that commitment include progress being made towards the development of an H5N1 vaccine global stockpile by the WHO, and efforts to establish an additional mechanism to ensure broader access to pandemic influenza vaccine for developing world countries.

Pandemic influenza poses a serious global public health threat with substantial estimated morbidity and mortality. The exact strain that may cause an influenza pandemic cannot be accurately predicted. Some experts, however, believe that the avian H5N1 strain, now endemic in many bird species across the world, is a likely candidate pandemic strain. A pandemic vaccine would not be available until 4-6 months after a pandemic strain has been identified, highlighting the need for earlier access to protection.

 

Article continues below and (thank you)
 

GSK has been working on an H5N1 flu vaccine since 1995. In March, the company announced data that demonstrated GSK’s proprietary adjuvanted candidate H5N1 vaccine, containing very low levels of antigen (3.8µg), elicits a strong cross-immune neutralizing antibody response in humans. These recent clinical data point to the potential public health benefits of creating a stockpile of pandemic influenza vaccine.

Jean-Pierre Garnier, CEO GlaxoSmithKline said: “We share a common goal with the WHO: to deliver as much vaccine as possible to the people who need it most in the face of a pandemic flu outbreak. We will contribute to that initiative by continuing to collaborate with WHO and worldwide authorities to find a global solution to this potential healthcare crisis.”

 
 
 
Google
Web www.iconocast.com
 
 
Continue News With: News9A ; ALL THE NEWS : News1 ; News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

 © 2002-2006

Keywords:

Contact Iconocast